OTCMKTS:CNBTF Cannara Biotech (CNBTF) Stock Price, News & Analysis $1.16 0.00 (0.00%) As of 06/18/2026 Add Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Cannara Biotech Stock (OTCMKTS:CNBTF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cannara Biotech alerts:Sign Up Key Stats Today's Range$1.16▼$1.1650-Day Range$1.16▼$1.4052-Week Range$0.08▼$0.20VolumeN/AAverage Volume33,127 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cannara Biotech Holdings Inc (OTCMKTS:CNBTF) is a biotechnology and natural health company focused on the development, production and distribution of plant-derived formulations, including cannabinoid-based products. Headquartered in Canada, the company integrates research and development with large-scale extraction and formulation processes to serve the pharmaceutical, cosmetic and wellness industries. The company’s offerings comprise high-purity botanical extracts, nutraceutical ingredients and cosmetic actives developed using proprietary extraction and purification techniques. In addition to finished product lines, Cannara Biotech provides contract research and toll-manufacturing services, supporting partners in the development and scale-up of plant-based formulations under quality-controlled conditions. Through GMP-aligned processing facilities, Cannara Biotech maintains rigorous quality assurance across its production network. While detailed corporate history and executive leadership information are limited in public disclosures, the company remains focused on expanding its biotechnological capabilities and strategic collaborations to address emerging market demands in natural health and wellness.AI Generated. May Contain Errors. Read More Receive CNBTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cannara Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNBTF Stock News HeadlinesCannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in QuébecApril 14, 2026 | markets.businessinsider.comVideo - CEO Clips: Cannara Biotech Graduates to Toronto Stock ExchangeMarch 19, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.June 20 at 1:00 AM | Profits Run (Ad)Cannara Reports Q1 Fiscal 2026 Results, Delivers New Record Financial Results, Extends Market Share Gains and Advances Disciplined Expansion StrategyJanuary 26, 2026 | markets.businessinsider.comCannara Biotech provides update on Quebec vape category launchJanuary 2, 2026 | msn.comCannara Biotech (LOVFF) price target increased by 18.60% to 2.58December 22, 2025 | msn.comCannara Biotech reports FY25 EPS C$0.14 vs. C$0.07 last yearNovember 24, 2025 | msn.comCannara Biotech announces proposed setllement of convertible debentureOctober 2, 2025 | msn.comSee More Headlines CNBTF Stock Analysis - Frequently Asked Questions How have CNBTF shares performed this year? Cannara Biotech's stock was trading at $1.27 at the start of the year. Since then, CNBTF stock has decreased by 8.8% and is now trading at $1.1580. How do I buy shares of Cannara Biotech? Shares of CNBTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:CNBTF CIKN/A Webcannara.ca PhoneN/AFaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:CNBTF) was last updated on 6/20/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cannara Biotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Cannara Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.